Stockscreener 앱 받기
79.52
0.19%
0.15
시간 외 거래:
81.06
1.54
+1.94%
Celcuity Inc 주식(CELC)의 최신 뉴스
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug - Stocktwits
Celcuity Inc.Common Stock (NQ: CELC - The Chronicle-Journal
Celcuity Inc. (CELC) Stock Analysis: Unpacking An 89.32% Potential Upside In Biotech - DirectorsTalk Interviews
Celcuity, Fluence Energy, Salesforce - tradingview.com
CELC Initiates Coverage On JP Morgan -- Rating Set to Overweight - GuruFocus
Celcuity Initiated at Overweight by JP Morgan - Moomoo
JPMorgan Initiates Celcuity With Overweight Rating, $157 Price Target - marketscreener.com
JPMorgan initiates Celcuity stock coverage with overweight rating By Investing.com - Investing.com India
JPMorgan initiates Celcuity stock coverage with overweight rating - Investing.com
CELC Stock Records Worst Day Ever After Late-Stage Breast Cancer Trial Results — What’s Driving The Selloff? - Stocktwits
Trading Systems Reacting to (CELC) Volatility - Stock Traders Daily
Transcript : Celcuity Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Celcuity at citigroup’s biopharma back to school summit: launch begins By Investing.com - Investing.com India
Celcuity at Wells Fargo healthcare conference: launch, data in focus By Investing.com - Investing.com Canada
Celcuity Stock Price Forecast. Should You Buy CELC? - StockInvest.us
Celcuity (CELC) Could Be 40% Undervalued After REVTORPYK FDA Filing - simplywall.st
Celcuity To Participate in Upcoming Investor Conferences - The Manila Times
How Investors May Respond To Celcuity (CELC) sNDA For REVTORPYK In PIK3CA-Mutant Breast Cancer - simplywall.st
What Could Celcuity (CELC) Gain If The FDA Clears REVTORPYK For Breast Cancer? - simplywall.st
Celcuity (CELC): Landmark Approval Collides With A Costly Launch - Yahoo Finance
Celcuity submits application for breast cancer drug expansion - Investing.com
Celcuity’s three-drug breast cancer treatment cut progression or death risk 50% vs. alpelisib - Stock Titan
Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer - Yahoo Finance
Celcuity (CELC) Technicals: Finishes 2.93% Down at $90.79 in the Latest Reading; Levels: Price Remains Between $86.25 Support and $95.33 ResistanceSpring Pattern - careplusvn.com
Celcuity Inc (CELC) Stock News Today - TradingKey
Celcuity (CELC) Q2 2026 Earnings Call Transcript - AOL.com
Celcuity (CELC) Quarter in Focus: EPS Comes in Below Forecast in the Current Update; Closing Move: Shares Move 2.79% Down in the Available RecordEarnings Weakness Phase - vinanet.vn
E Fund Management Co. Ltd. Purchases New Holdings in Celcuity, Inc. $CELC - MarketBeat
Celcuity (NASDAQ: CELC) insider updates stock holdings - Stock Titan
Craig-Hallum Maintains Celcuity(CELC.US) With Buy Rating, Cuts Target Price to $173 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Celcuity's (CELC) "Market Outperform" Rating Reiterated at Citizens Jmp - MarketBeat
Celcuity awaits FDA review for second factory to launch cancer drug - Endpoints News
Guggenheim raises Celcuity stock price target on drug pricing data By Investing.com - Investing.com Nigeria
Guggenheim raises Celcuity stock price target on drug pricing data - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update - Investing.com
H.C. Wainwright reiterates Celcuity stock rating on pricing update By Investing.com - Investing.com South Africa
Getting To A First Product Approval With Celcuity's Brian Sullivan｜Business Of Biotech - finance.biggo.com
Citizens reiterates Celcuity stock rating ahead of drug launch By Investing.com - Investing.com South Africa
Citizens reiterates Celcuity stock rating ahead of drug launch - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Celcuity Inc. (CELC) Investors to Inquire about Securities Investigation - The National Law Review
Brian Sullivan: The $20 Million Bet That Resurrected Pfizer's Shelved Cancer Drug - finance.biggo.com
Is Celcuity (CELC) A Bargain As Losses Widen Ahead Of Its First Launch? - Yahoo Finance
How Investors May Respond To Celcuity (CELC) Winning FDA Nod For Revtopik Amid Wider Quarterly Loss - Yahoo Finance
The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status - simplywall.st
3.06%
2.55%
자본화:
|
볼륨(24시간):